Market Overview

UPDATE: Deutsche Bank Upgrades Tenet Healthcare to Buy on Compelling Outlook

Share:
Related THC
Credit Suisse: A Beaten Down Tenet Healthcare 'Still Strong'
UPDATE: Tenet Healthcare Reports Q4 Profit

Deutsche Bank raised its rating on Tenet Healthcare (NYSE: THC) from Hold to Buy and increased its price target from $31 to $38.

Deutsche Bank noted, "Our upgrade is underpinned by: (1) clear signs of improving business mix and margins due especially to gains in outpatient, (2) tangible momentum in Conifer, and (3) a more sustainable FCF profile going forward. We also continue to highlight the upside risks due to PPACA, and note our 2014 EPS of $3.85 is 17% above consensus. Due to a more favorable outlook, we believe THC should be positioned to garner an in-line (~6x) fwd EV/EBITDA multiple."

Tenet Healthcare closed at $30.63 on Thursday.

Latest Ratings for THC

DateFirmActionFromTo
Feb 2015CitigroupMaintainsBuy
Feb 2015BMO CapitalUpgradesMarket PerformOutperform
Feb 2015JP MorganMaintainsOverweight

View More Analyst Ratings for THC
View the Latest Analyst Ratings

Posted-In: Deutsche BankAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings

 

Related Articles (THC)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Our Experts vs. S&P 500Powered by Benzinga
Marketfy Products Return S&P 500
Morning Profit Maker 42.72% 6.69%
The Option Prophet 91.14% 6.69%
SecretCaps 26.55% 6.69%
Short-Term Trend Trading 11.89% 6.69%
View the highest rated products→